Our previous work showed that trastuzumab treatment of cancer cells alone did not downregulate HER2 level in vitro, but we detected HER2 downregulation in mouse xenograft tumors when treated with trastuzumab [25], suggesting that immune cells might play a role in the HER2 downregulation by trastuzumab in vivo. Here, ERBB2 is linked to cancer.